SCHEMBL6538995

SCHEMBL6538995

O=[C]COCc1cccc2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
PARP10 Q53GL7 1/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP2C9 P11712 1/20 0.44
ACP3 P15309 1/20 0.43
SLC1A3 P43003 1/20 0.43
SLC1A2 P43004 1/20 0.43
SLC1A1 P43005 1/20 0.43
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
ATM Q13315 1/20 0.42
CYP2D6 P10635 1/20 0.42
MTNR1A P48039 1/20 0.41
FFAR1 O14842 1/20 0.41
AKR1B1 P15121 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6538978 0.83 MEN1 (0.42) TDP1MEN1KMT2ANPC1RAB9A
SCHEMBL4850585 0.82 CYP1A2 (0.56) TDP1MEN1KMT2ANPC1RAB9A
SCHEMBL31012122 0.82 CYP1A2 (0.56) TDP1MEN1KMT2ANPC1RAB9A
SCHEMBL7958968 0.82 CYP1A2 (0.44) TDP1MEN1KMT2ANPC1RAB9A
SCHEMBL7067038 0.79 CYP1A2 (0.43) TDP1MEN1KMT2ANPC1RAB9A
SCHEMBL29852 0.78 TDP1 (0.47) TDP1MEN1KMT2ANPC1RAB9A
Hydroxyamine SCHEMBL8924246 0.77 MEN1 (0.53) TDP1MEN1KMT2APARP10CYP1A2
Sulfuric Acid SCHEMBL28586052 0.76 TDP1 (0.50) TDP1MEN1KMT2ANPC1RAB9A
SCHEMBL10815296 0.76 CYP1A2 (0.48) TDP1MEN1KMT2ANPC1RAB9A
SCHEMBL327701 0.76 CYP1A2 (0.50) TDP1MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812235-B2 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-02 US disclosed
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ASTELLAS PHARMA INC. (JP) 2003-01-23 US disclosed
EP-1255748-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-13 EP disclosed
WO-2001060813-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ARRB1, ADRB1, GLRB TDP1 4505/4885MEN1 1428/4885KMT2A 2770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.